arrow
B

Begoña Mellado

hospital clinic
H指数:48
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Corrigendum to “Prognostic Expression Signature of RB1, PTEN, and TP53 Genes in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors” [Eur. Urol. Open Sci. 70 (2024) 86–90]

勘误:“接受雄激素受体通路抑制剂治疗的有转移性激素敏感性前列腺癌患者中RB1、PTEN和TP53基因的预后表达特征”[Eur. Urol. Open Sci. 70 (2024) 86–90]

2025-06-040
OA
Corrigendum to “Development and independent validation of a prognostic gene expression signature based on RB1, PTEN, and TP53 in metastatic hormone-sensitive prostate cancer patients” [Eur. Urol. Oncol. 7 (2024) 954–964]

勘误:关于“基于RB1、PTEN和TP53在转移性激素敏感性前列腺癌患者中开发并独立验证预后基因表达签名”[Eur. Urol. Oncol. 7 (2024) 954–964]

2025-05-010
PRE
Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial

非透明细胞肾细胞癌中,伊匹木单抗/纳武利尤单抗对比标准护理的 prospective randomized phase-II trial - SUNNIFORECAST trial 的结果

2025-04-010
OA
Considerations for hereditary breast and ovarian cancer syndrome molecular diagnosis: experience from the clinical practice
2025-02-240
PRE
Prognostic Expression Signature of RB1, PTEN, and TP53 Genes in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors

雄激素受体途径抑制剂治疗的转移性激素敏感型前列腺癌患者RB1、PTEN和TP53基因的预后表达特征

2024-12-011
PRE
Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study

诱导avelumab,然后进行化学免疫疗法和维持与单独化疗作为顺式不合格转移性尿路上皮癌的一线治疗 (INDUCOMAIN): 一项随机II期研究

2024-09-010
OAAI
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

177Lu-PSMA-617与雄激素受体途径抑制剂治疗的变化对紫杉烷初治的进行性转移性去势抵抗性前列腺癌患者 (PSMAfore): 一项3期随机对照试验

LANCET
IF88.5
2024-09-014
PRE
Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients
2024-08-014
OA
Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1)
2023-12-153
PRE
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study
2023-11-030
OAAI
Management of Fibroblast Growth Factor Inhibitor Treatment- emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
2023-04-017
OAAI
Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study
2022-10-265
OA
Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial

在一线醋酸阿比曲酮或恩扎鲁他胺治疗无症状骨转移的转移性去势抵抗性前列腺癌患者的镭223: 一项单臂II期试验

2022-09-017
PRE
Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy
2022-04-0112
OAAI